These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35005587)

  • 1. Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis.
    Generali E; Carrara G; Bortoluzzi A; De Santis M; Ceribelli A; Scirè CA; Selmi C
    J Transl Autoimmun; 2021; 4():100113. PubMed ID: 35005587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
    Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH
    Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 6. First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine.
    Jacobs ME; Pouw JN; Welsing P; Radstake TRDJ; Leijten EFA
    Rheumatology (Oxford); 2021 Feb; 60(2):780-784. PubMed ID: 32797218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
    Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
    Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
    Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
    Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
    Kawai VK; Grijalva CG; Arbogast PG; Curtis JR; Solomon DH; Delzell E; Chen L; Ouellet-Hellstrom R; Herrinton L; Liu L; Mitchel EF; Stein CM; Griffin MR
    Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1415-24. PubMed ID: 22121511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Soliman MM; Ashcroft DM; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2011 Apr; 70(4):583-9. PubMed ID: 21330639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
    Wisłowska M; Jakubicz D
    Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
    Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
    BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate.
    Malesci D; Tirri R; Buono R; La Montagna G
    Clin Exp Rheumatol; 2007; 25(6):881-4. PubMed ID: 18173924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate: optimizing the efficacy in rheumatoid arthritis.
    Braun J
    Ther Adv Musculoskelet Dis; 2011 Jun; 3(3):151-8. PubMed ID: 22870474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
    Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
    Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs.
    Marchesoni A; Lubrano E; Cauli A; Ricci M; Manara M
    J Rheumatol Suppl; 2015 Nov; 93():61-4. PubMed ID: 26523060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.
    Busger Op Vollenbroek FTM; Doggen CJM; Janssens RWA; Bernelot Moens HJ
    PLoS One; 2018; 13(3):e0194401. PubMed ID: 29570708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.